Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development

被引：23
|
作者：
Hargrove-Grimes, Passley [1 ]
Low, Lucie A. [1 ]
Tagle, Danilo A. [1 ]
机构：
[1] NIH, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA
来源：
CELLS TISSUES ORGANS | 2022年 / 211卷 / 03期
关键词：
Microphysiological systems; Microfluidics; Bioengineering; Induced pluripotent stem cells; Drug development; ON-A-CHIP; PLURIPOTENT STEM-CELLS; PHARMACEUTICAL-INDUSTRY; SAFETY ASSESSMENT; ORGANS; DEVICES; MODELS; ABSORPTION; INDUCTION; EFFICACY;
D O I：
10.1159/000517422
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
Microphysiological systems (MPS) or tissue chips/organs-on-chips are novel in vitro models that emulate human physiology at the most basic functional level. In this review, we discuss various hurdles to widespread adoption of MPS technology focusing on issues from multiple stakeholder sectors, e.g., academic MPS developers, commercial suppliers of platforms, the pharmaceutical and biotechnology industries, and regulatory organizations. Broad adoption of MPS technology has thus far been limited by a gap in translation between platform developers, end-users, regulatory agencies, and the pharmaceutical industry. In this brief review, we offer a perspective on the existing barriers and how end-users may help surmount these obstacles to achieve broader adoption of MPS technology.
引用
收藏
页码：269 / 281
页数：13
相关论文
共 50 条
  • [41] Vascular microphysiological systems
    Shelton, Sarah E.
    [J]. CURRENT OPINION IN HEMATOLOGY, 2024, 31 (03) : 155 - 161
  • [42] Gastrointestinal microphysiological systems
    Blutt, Sarah E.
    Broughman, James R.
    Zou, Winnie
    Zeng, Xi-Lei
    Karandikar, Umesh C.
    In, Julie
    Zachos, Nicholas C.
    Kovbasnjuk, Olga
    Donowitz, Mark
    Estes, Mary K.
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2017, 242 (16) : 1633 - 1642
  • [43] Microphysiological systems meet hiPSC technology - New tools for disease modeling of liver infections in basic research and drug development
    Raasch, Martin
    Fritsche, Enrico
    Kurtz, Andreas
    Bauer, Michael
    Mosig, Alexander S.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2019, 140 : 51 - 67
  • [44] Drug development in Japan: Opportunities and challenges in drug development
    Takahashi K.
    [J]. International Journal of Pharmaceutical Medicine, 2007, 21 (5): : 331 - 338
  • [45] Advanced hepatic drug safety assessment: 3D & microphysiological systems
    Williams, D. P.
    [J]. TOXICOLOGY LETTERS, 2018, 295 : S21 - S22
  • [46] Proliposome-Based Nanostrategies: Challenges and Development as Drug Delivery Systems
    Mangilal Choudhary
    Nishtha Chaurawal
    Md. Abul Barkat
    Kaisar Raza
    [J]. AAPS PharmSciTech, 23
  • [47] Challenges in the development and establishment of exosome-based drug delivery systems
    Wang, Jin
    Chen, Derek
    Ho, Emmanuel A.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 329 : 894 - 906
  • [48] Proliposome-Based Nanostrategies: Challenges and Development as Drug Delivery Systems
    Choudhary, Mangilal
    Chaurawal, Nishtha
    Abul Barkat, Md
    Raza, Kaisar
    [J]. AAPS PHARMSCITECH, 2022, 23 (08)
  • [49] Microphysiological systems of the placental barrier
    Arumugasaamy, Navein
    Rock, Kylie D.
    Kuo, Che-Ying
    Bale, Tracy L.
    Fisher, John P.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2020, 161 : 161 - 175
  • [50] Drug Development and Market Challenge: Charity Stakeholder Perspective
    Richards, S.
    Knox, L.
    Bird, N.
    Rogers, J.
    Ludwinski, D.
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 : S344 - S344
12345